In our opinion, from a practical point of view, the high expression of FOXA1 in ER + BC may allow for predicting a good prognostic outcome, potentially supporting the clinicians’ decision to omit chemotherapy (also as a neoadjuvant approach) in luminal BC. This evidence concerns the gene FOXA1 and breast cancer.